VMI
PTGX icon

VHCP Management II’s Protagonist Therapeutics PTGX Stock Holding History

VHCP Management II’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$227K Sell
32,211
-394,570
-92% -$3.92M 0.06% 20
2019
Q3 		$5.13M Hold
426,781
– – 1.95% 9
2019
Q2 		$5.17M Buy
426,781
+155,404
+57% +$1.72M 1.63% 14
2019
Q1 		$3.41M Buy
271,377
+21,353
+9% +$188K 1% 14
2018
Q4 		$1.68M Buy
+250,024
New +$1.98M 0.72% 17

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VHCP Management II's PTGX Position: Q4 2019 in Review

VHCP Management II reduced its Protagonist Therapeutics (PTGX) stake by 92% in Q4 2019, selling an estimated $3.92M and leaving 32,211 shares worth $227K. The position accounts for 0.06% of the portfolio, ranked #20.

VHCP Management II first reported a position in PTGX in Q4 2018 and has held it in 5 quarters since. The position peaked at $5.17M in Q2 2019. 81 funds tracked by Wall St. Rank hold PTGX as of Q4 2019.

  • VHCP Management II held 32,211 shares of Protagonist Therapeutics worth $227K as of Q4 2019.
  • VHCP Management II sold 394,570 Protagonist Therapeutics shares in Q4 2019, an estimated $3.92M.
  • Protagonist Therapeutics made up 0.06% of VHCP Management II's portfolio in Q4 2019, its #20 holding.
  • VHCP Management II first reported a position in Protagonist Therapeutics in Q4 2018 and has held it in 5 quarters since.
  • VHCP Management II's Protagonist Therapeutics position peaked at $5.17M in Q2 2019.
  • 81 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2019.

Based on VHCP Management II's 13F filing for Q4 2019, filed 13 Feb 2020.